Abstract: SA-PO0831
Comparison of Efficacy and Safety Among Four Therapeutic Regimens in Primary Membranous Nephropathy with High Phospholipase A2 Receptor (PLA2R) Antibody Titers: A Single-Center Retrospective Cohort Study
Session Information
- Glomerular Diseases: Management, Evolving Strategies, and Practice-Changing Advances
October 24, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics
Authors
- Huang, Yuxiu, Nephrology Medical Center, Weifang People’s Hospital, Weifang, Shandong, China
- Meng, Xinxuan, Nephrology Medical Center, Weifang People’s Hospital, Weifang, Shandong, China
- Wu, Shengqin, Nephrology Medical Center, Weifang People’s Hospital, Weifang, Shandong, China
- Miao, Xia, Nephrology Medical Center, Weifang People’s Hospital, Weifang, Shandong, China
- Qin, Lili, Nephrology Medical Center, Weifang People’s Hospital, Weifang, Shandong, China
- Zhang, Kunying, Nephrology Medical Center, Weifang People’s Hospital, Weifang, Shandong, China
- Sun, Jingshu, Nephrology Medical Center, Weifang People’s Hospital, Weifang, Shandong, China
- Wang, Jianying, Nephrology Medical Center, Weifang People’s Hospital, Weifang, Shandong, China
Background
We conducted a retrospective study to compare the efficacy and safety of four regimens in this high-risk population: rituximab monotherapy, tacrolimus plus glucocorticoids, rituximab plus cyclosporine, and cyclophosphamide plus glucocorticoids
Methods
We retrospectively enrolled 185 patients with biopsy-proven PMNs and anti-PLA2R titers > 150 RU/mL. The primary outcome was total remission (TR) at 24 months, and the secondary outcomes included complete remission (CR), partial remission (PR), immunological remission (IR), relapse rate, time to remission, and adverse events.
Results
At 24 months, the TR rates were 54.5% for the RTX regimen, 52.2% for the TAC regimen, 76% for the RTX plus CsA regimen, and 73.3% for the CTX regimen. Kaplan–Meier analysis revealed significant differences in cumulative IR rate, cumulative CR rate, and cumulative TR rate among the four regimens. The TAC regimen had a significantly higher relapse rate than the RTX plus CsA regimen.
Conclusion
The RTX plus CsA regimen was comparable in efficacy to the CTX regimen in inducing clinical and immunological remission and superior to both the RTX and TAC regimens with lower relapse rates and no serious adverse events. The RTX plus CsA regimen may be more effective and safer and could serve as a promising therapeutic option for patients with PMN with high anti-PLA2R antibody titers.